Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Trevi Therapeutics, Inc is a biotechnology business based in the US. Trevi Therapeutics shares (TRVI) are listed on the NASDAQ and all prices are listed in US Dollars. Trevi Therapeutics employs 22 staff and has a market cap (total outstanding shares value) of USD$56.6 million.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Mobile users
Latest market close | USD$2.86 |
---|---|
52-week range | USD$1.33 - USD$8.49 |
50-day moving average | USD$3.335 |
200-day moving average | USD$4.2092 |
Wall St. target price | USD$11 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-9.144 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.86 from 2020-12-09
1 week (2021-01-12) | N/A |
---|---|
1 month (2020-12-23) | 7.12% |
3 months (2020-10-19) | N/A |
6 months (2020-07-19) | N/A |
1 year (2020-01-19) | N/A |
---|---|
2 years (2019-01-19) | N/A |
3 years (2018-01-19) | N/A |
5 years (2016-01-19) | N/A |
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -30.83% |
Return on equity TTM | -61.81% |
Profit margin | 0% |
Book value | $1.944 |
Market capitalisation | USD$56.6 million |
TTM: trailing 12 months
There are currently 44,988 Trevi Therapeutics shares held short by investors – that's known as Trevi Therapeutics's "short interest". This figure is 5.9% down from 47,788 last month.
There are a few different ways that this level of interest in shorting Trevi Therapeutics shares can be evaluated.
Trevi Therapeutics's "short interest ratio" (SIR) is the quantity of Trevi Therapeutics shares currently shorted divided by the average quantity of Trevi Therapeutics shares traded daily (recently around 18287.804878049). Trevi Therapeutics's SIR currently stands at 2.46. In other words for every 100,000 Trevi Therapeutics shares traded daily on the market, roughly 2460 shares are currently held short.
However Trevi Therapeutics's short interest can also be evaluated against the total number of Trevi Therapeutics shares, or, against the total number of tradable Trevi Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Trevi Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Trevi Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0081% of the tradable shares (for every 100,000 tradable Trevi Therapeutics shares, roughly 8 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Trevi Therapeutics.
Find out more about how you can short Trevi Therapeutics stock.
We're not expecting Trevi Therapeutics to pay a dividend over the next 12 months.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Its Haduvio (nalbuphine ER), which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. The company was founded in 2011 and is headquartered in New Haven, Connecticut.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.